Almac today announced the expansion of its clinical services and
technologies capabilities to include on-the-ground leadership as well as
technical, project and operational resources in Asia. The company has
established regional hubs in Singapore and Japan to better enable the
industry's growing need to conduct clinical trials in Asia and/or manage
global trials from the region. Local teams apply insights gained from
Almac's experience managing more than 10,000 trials around the world to
design, implement and manage drug supply strategies and efficient
technology solutions throughout the life of the study.
"From protocol to patient to kit destruction, Almac delivers high
quality, flexible and cost-effective solutions that enable a more
comprehensive approach to trial supply management," says Alan Armstrong,
CEO, Almac. "No one else can provide the global scale, scope and reach
required to optimize sponsors' R&D investments across every facet of the
supply chain - within Asia or around the world."
Providing expert and responsive service is essential for all trials, but
particularly those managed from or within Asia. Sponsors must be able to
navigate technical, logistical and clinical complexities from trial
start-up through to supply and patient management. Almac's local teams
support studies of all sizes and degrees of complexity, helping sponsors
to achieve time-saving efficiencies, reduce costs and improve trial
outcomes. Services are augmented by a secure, web-based interface to
monitor trial execution anywhere in the world, multi-lingual technical
and project teams, and an in-house 24 x 7 x 365 hotline connecting site
staff to on-call clinicians and unblinding specialists. By positioning
operational resources within the same time zones as where trials are
executed, Almac is able to resolve issues in less than 24 hours - which
in turn eliminates communications delays and improves patient care.
Almac is strengthening its Asia Pacific offerings by establishing a new
secondary packaging facility in Singapore that ill open by the end of
2014. Through this facility, the company will better enable just-in-time
supply management and support drug pooling strategies, which further
optimize the supply chain, minimize wastage and reduce costs.
"With 15 percent of all clinical trials conducted in Asia, it's
imperative that we provide localized service and support to our
clients," continues Armstrong. "We've long managed clinical trials on a
global basis, but there's now sufficient critical mass that requires we
establish dedicated resources in the region. I'm pleased that our
international expertise and global capabilities are now even more
accessible to sponsors in this critically-important part of the world,
and look forward to opening our new packaging facility later this year."
About Almac Group
'Partnering to Advance Human Health'
The Almac Group is an established contract development and manufacturing
organisation that provides an extensive range of integrated services to
over 600 companies globally within the pharmaceutical and biotech
sectors. The services range from R&D,
discovery and development, API
trial supply, IXRS®
technology (IVRS/IWRS) through to commercial-scale
The international company is a privately owned organisation that has
organically grown over 30 years and now employs in excess of 3,300
highly skilled personnel. Almac is headquartered in Craigavon, Northern
Ireland with operations across the US (Pennsylvania, North Carolina and
California) and in Asia (Singapore and Tokyo).
[ Back To NFVZone's Homepage ]